Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

45 results about "Feeding disorder" patented technology

A feeding disorder, in infancy or early childhood, is a child's refusal to eat certain food groups, textures, solids or liquids for a period of at least one month, which causes the child to not gain enough weight, grow naturally or cause any developmental delays. Feeding disorders resemble failure to thrive, except that at times in feeding disorder there is no medical or physiological condition that can explain the very small amount of food the children consume or their lack of growth. Some of the times, a previous medical condition that has been resolved is causing the issue.

External pulse generator for adjunct (add-on) treatment of obesity, eating disorders, neurological, neuropsychiatric, and urological disorders

An external pulse generator comprising a primary coil and adapted to inductively couple to an implanted receiving means, is designed to deliver neuromodulation therapy for disorders comprising obesity, eating disorders, anxiety and the like. The external pulse generator contains limited number of predetermined programs. These programs provide the patient or caretaker a means to adjust the therapy within confined limits, or turn the device off. The predetermined programs contain unique combination of pulse amplitude, pulse width, frequency of stimulation, and on-off time. In another mode of operation, the parameters can be individually adjusted and the stimulation therapy program can be “customized” for the patient, and stored in the memory. The programs are capable of being modified with a programming station connected to the pulse generator with a RS232-C serial connection. Additionally, the external pulse generator has two-way wireless capabilities, whereby enabling the physicians to remotely control the therapy programs of their patients using wireless internet. Moreover, the external pulse generator has proximity sensing and feedback regulation component to provide a constant therapy in accordance with the predetermined programs.
Owner:NEURO & CARDIAC TECH

Use of exendins for the reduction of food intake

Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. The methods are also useful for lowering the plasma glucose level, lowering the plasma lipid level, reducing the cardiac risk, reducing the appetite, and reducing the weight of subjects. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Owner:ASTRAZENECA PHARMA LP

Obesity and eating disorder stimulation treatment with neural block

A method and apparatus for treating patients suffering from obesity or eating disorders by applying a predetermined stimulating signal to the patient's vagus nerve appropriate to alleviate the condition and by applying a neural conduction block to the vagus nerve at a blocking site with the neural conduction block selected to at least partially block nerve impulses on the vagus nerve at the blocking site.
Owner:RESHAPE LIFESCIENCES INC

Gip analog and hybrid polypeptides with selectable properties

ActiveUS20080312157A1Increased insulin secretionDecreasing bone loss bonePeptide/protein ingredientsMetabolism disorderDyslipidemiaFeeding disability
The present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and / or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
Owner:ASTRAZENECA PHARMA LP

Dynamic nerve stimulation in combination with other eating disorder treatment modalities

InactiveUS20080262411A1Provide central nervous system satietyIncreased energy expenditureBiocideOrganic active ingredientsDiseaseWeight-loss drugs
A method for the treatment of obesity or other disorders by electrical activation or inhibition of nerves is disclosed. This activation or inhibition can be accomplished by stimulating a nerve using an electrode. The method further comprises performing a surgical procedure and / or administering a weight loss drug.
Owner:ADVANCED NEUROMODULATION SYST INC

Methods and apparatus for delivering a drug influencing appetite for treatment of eating disorders

Methods and systems for treating patients suffering from eating disorders, e.g. obesity, through the dispensation of a drug by an implantable infusion pump (IIP) delivering drug into the cerebral spinal fluid (CSF) at a site of the intrathecal space in amounts and at times effective to suppress the patient's appetite through interaction of the drug transported through the CSF with receptors in the brain. Delivery of a programmed drug dosage is preferably by one of time-out of programmed time(s) of day, a command received from the patient, or a trigger signal developed from a sensed GI tract signal accompanying peristalsis.
Owner:MEDTRONIC INC

Treatment of pathologic craving and aversion syndromes and eating disorders by electrical brain stimulation and/or drug infusion

Systems and methods for introducing one or more stimulating drugs and / or applying electrical stimulation to the brain to at least treat or prevent obesity and / or other eating disorders, as well as drug, nicotine and alcohol addiction, uses at least one system control unit (SCU) producing electrical pulses delivered via electrodes implanted in the brain and / or producing drug infusion pulses, wherein the stimulating drug(s) are delivered to targeted areas in the brain.
Owner:BOSTON SCI NEUROMODULATION CORP

Photoreceptor system for melatonin regulation and phototherapy

The present invention involves a light system for stimulating or regulating neuroendocrine, circadian, and photoneural systems in mammals based upon the discovery of peak sensitivity ranging from 425-505 nm; a light meter system for quantifying light which stimulates or regulates mammalian circadian, photoneural, and neuroendocrine systems. The present invention also relates to translucent and transparent materials, and lamps or other light sources with or without filters capable of stimulating or regulating neuroendocrine, circadian, and photoneural systems in mammals. Additionally, the present invention involves treatment of mammals with a wide variety of disorders or deficits, including light responsive disorders, eating disorders, menstrual cycle disorders, non-specific alerting and performance deficits, hormone-sensitive cancers, and cardiovascular disorders.
Owner:THOMAS JEFFERSON UNIV +2

DPP-IV Resistant GIP Hybrid Polypeptides with Selectable Properties

ActiveUS20110136737A1Increased insulin secretionDecreasing bone loss bonePeptide/protein ingredientsAntibody mimetics/scaffoldsDyslipidemiaFeeding disability
The Present invention relates generally to novel GIP analogs and GIP hybrid polypeptides with selectable properties, useful as agents for the treatment and prevention of metabolic diseases and disorders, for example those which can be alleviated by control plasma glucose levels, insulin levels, and / or insulin secretion, positive inotropic effects, reduction of catabolic effects, slowing of gastric emptying. Such conditions and disorders include, but are not limited to, hypertension, dyslipidemia, cardiovascular disease, eating disorders, critical care, insulin-resistance, obesity, and diabetes mellitus of any kind, including type 1, type 2, and gestational diabetes.
Owner:ASTRAZENECA PHARMA LP

Duodenal stimulation devices and methods for the treatment of conditions relating to eating disorders

A device useful for treatment of conditions relating to an eating disorder comprises: a) a duodenum obstructing component configured to partially obstruct the lumen of a duodenum in which deployed, preferably so as to reduce the rate of passage of materials through the duodenum; and b) an anchoring component configured to substantially maintain a position of the obstructing component inside a duodenum wherein deployed. The obstructing component does not block entry of food into the duodenum but rather causes a given volume of food that enters the duodenum to induce a greater degree of satiety and / or to induce a perception of satiety for a longer period of time and / or to induce a perception of satiety faster than otherwise.
Owner:DUOCURE

Combination of atypical antipsychotics and 5HT-1B receptor antagonists

InactiveUS20050256112A1Reduce morbidityDifferent recognizableNervous disorderMetabolism disorderDiseaseHeadaches
The present invention relates to a pharmaceutical composition for treating, for example, a disorder or condition selected from the group consisting of hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress disorder, avoidant personality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's diseases, endocrine disorders, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, Fibromyalgia Syndrome, stress incontinence, Tourette syndrome, trichotillomania, kleptomania, male impotence, cancer, chronic paroxysmal hemicrania and headache in a mammal, preferably a human, comprising (i) an atypical antipsychotic or a pharmaceutically acceptable salt thereof, (ii) a 5-HT1B receptor antagonist or a pharmaceutically acceptable salt thereof, wherein the 5-HT1B receptor antagonist is selected from the group consisting of (A) a compound of the formula I as described in the specification and (B) a compound of the formula II as described in the specification, and optionally (iii) a pharmaceutically acceptable carrier.
Owner:PFIZER INC

Methods for Selection of Melanocortin Receptor-Specific Agents for Treatment of Obesity

Provided are methods for selecting melanocortin receptor-specific compounds for attenuating food intake and for treatment of specific disease conditions, including treatment of obesity and related energy homeostasis or feeding disorders characterized by excess weight gain, without inducing a sexual response, and methods for selecting compounds for treatment of sexual dysfunction. Further provided are pharmaceutical preparations defined by such methods, and methods and preparations for attenuating food intake and treatment of said conditions.
Owner:PALATIN TECH INC

Bombesin receptor antagonists

Bombesin receptor antagonists are provided which are compounds of formula (I) or pharmaceutically acceptable salts thereof: wherein j, k, l, m, n, q, r, Ar, Ar<1>, R<1>, R<2>, R<3>, R<4>, R<5>, R<6 >and X are as defined in the description. The compounds of the invention have an affinity for the BB1 receptor and some of them also have affinity for the BB2 receptor. Accordingly they may be useful for the diagnosis, prevention, or treatment of male and female sexual dysfunction. They can also be used in the diagnosis, prevention or treatment of anxiety and panic disorders, social phobia, depression, psychoses, sleeping disorders, memory impairment, pulmonary hypertension, lung repair and lung development disorders, cancer including prostate cancer and pancreatic cancer, hepatic porphyria, gastrointestinal secretory disturbances, gastrointestinal disorders including colitis, Crohn's disease and inflammatory bowel disease, emesis, anorexia, pain, seasonal affective disorders, feeding disorders or pruritus.
Owner:WARNER-LAMBERT CO

Appendicular and rectal stimulator device for digestive and eating disorders

ActiveUS7930033B2Heart defibrillatorsExternal electrodesNervous systemEnteric nervous system
A method of using a stimulation device to emit a medium to an appendicular region and / or rectal region of a user for treatment of a gastrointestinal disorder is described. The method includes placing the stimulation device into the appendicular region and / or rectal region, and delivering the medium, wherein the medium stimulates at least a portion of the enteric nervous system. Additionally, apparatus and delivery devices are disclosed.
Owner:TRANSTIMULATION RES

Endothelin and Endothelin Receptor Agonists in the Treatment of Metabolic Diseases

Methods for treating conditions or disorders which can be alleviated by reducing food intake are disclosed which comprise administration of an effective amount of an endothelin or an endothelin agonist, alone or in conjunction with other compounds or compositions that affect satiety. The methods are useful for treating conditions or disorders, including obesity, Type II diabetes, eating disorders, and insulin-resistance syndrome. Pharmaceutical compositions for use in the methods of the invention are also disclosed.
Owner:AMYLIN PHARMA INC

Novel biological substance nesfatin and its related substances and uses thereof

InactiveCN101300346AIncrease hyperactive effectFungiBacteriaThiazolidinedioneAppetite regulation
The present invention relates to a novel method of obtaining a factor involved in appetite control and / or body weight control, as well as genes obtained by said method, polypeptides encoded by said genes, or novel polypeptides obtained from the information on polypeptides encoded by said genes as a means for treating, controlling or diagnosing diseases associated with eating disorders and / or bodyweight control. Also the present invention relates to substances that inhibit the effects of said genes or said polypeptides as a means for treating, controlling or diagnosing diseases associated with appetite control and / or body weight control. By using thiazolidine diones having a PPAR agonist activity, genes and polypeptides involved in appetite regulation and / or body weight reduction can be obtained. NESFATIN or the like obtained by said method can be used as a means for treating, controlling or diagnosing diseases associated with eating disorders and / or body weight control.
Owner:TEIJIN PHARMA CO LTD

Compounds acting on the serotonin transporter

InactiveUS20100048713A1Conducive to survival and growthEasy to learnBiocideHalogenated hydrocarbon active ingredientsDiseasePanic
The invention relates to new chemical compounds acting on the serotonin transporter (SERT), and associated pharmaceutical compositions, methods for use as therapeutic agents, and methods of preparation thereof. In particular the new chemical compounds are useful for the treatment of a variety of central nervous system (CNS) disorders—for example anxiety, depression, epilepsy, obsessive-compulsive disorders, migraine, cognitive disorders, sleep disorders, feeding disorders, panic attacks, disorders related to withdrawl from drug abuse, schizophrenia, or the like, or in the treatment of gastrointestinal disorders such as irritable bowel syndrome.
Owner:AARHUS UNIV +1

Pyrimidine derivatives and methods of treatment related to the use thereof

InactiveUS20090036448A1Reduces food intakeInduce satietyBiocideOrganic active ingredientsSubstance abuserBinge-eating disorder
The present invention encompasses novel substituted pyrimidine compounds of Formula (I): which act as MCH receptor antagonists. These compounds are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of improving memory function, sleeping and arousal, anxiety, depression, mood disorders, seizure, obesity, diabetes, appetite and eating disorders, cardiovascular disease, hypertension, dyslipidemia, myocardial infarction, binge eating disorders including bulimia, anorexia, mental disorders including manic depression, schizophrenia, delirium, dementia, stress, cognitive disorders, attention deficit disorder, substance abuse disorders and dyskinesias including Parkinson's disease, epilepsy, and addiction.
Owner:TAISHO PHARMACEUTICAL CO LTD +1

Modified Dynorphin Expression in Animals and Identification of Compounds for Treatment of Obesity and Diabetes

The present invention provides novel transgenic animal models of reduced dynorphin expression in humans that are useful for identifying compounds that are antagonists, inverse agonists, agonists or mimetics of one or more dynorphin peptide products of preprodynorphin. The compounds identified in such screening assays are useful in contexts related to the treatment of obesity and type II diabetes including, for example, improving weight loss and / or reducing appetite during dieting; treating feeding disorders; and for modifying fat mass and reducing glucose intolerance in males.
Owner:GARVAN INST OF MEDICAL RES

Desacyl ghrelin antibodies and therapeutic uses thereof

A neutralizing epitope is identified within amino acids 1-3 of desacyl ghrelin. Antibodies that bind this epitope fall within the scope of the invention and can be murine, chimeric, or humanized antibodies, immunoconjugates of the antibodies, or antigen-binding fragments thereof. The antibodies of the invention are useful for the treatment or prevention of obesity and related disorders including, for example, Type II non-insulin dependent diabetes mellitus (NIDDM), Prader-Willi syndrome, eating disorders, hyperphagia, and impaired satiety. Additionally, such antibodies can be useful for the treatment or prevention of other disorders, including anxiety, gastric motility disorders (including e.g., irritable bowel syndrome and functional dyspepsia), insulin resistance syndrome, metabolic syndrome, dyslipidemia, atherosclerosis, hypertension, hyperandrogenism, polycystic ovarian syndrome, cancer, and cardiovascular disorders by administering a therapeutically effective amount of an anti-desacyl ghrelin monoclonal antibody of the invention.
Owner:ELI LILLY & CO

Double-rotor scrap steel crusher and crushing method

The invention discloses a double-rotor scrap steel crusher. The double-rotor scrap steel crusher comprises a feeding groove and a crushing bin, wherein the crushing bin comprises a box body and at least two crushing shafts, the crushing shafts are rotationally arranged in the box body in a driven mode, a plurality of crushing hammers are arranged on the crushing shafts, and a feeding hole of the crushing bin is positioned above one sides of the end parts of the crushing shafts. According to the double-rotor scrap steel crusher, the feeding mode that feeding is carried out above the end sides of the crushing shafts is adopted in a breakthrough mode, so that crushed materials are crushed while axially advancing along the crushing shafts, the crushing time is long, the breaking and striking points are large, and the large pieces of materials can be effectively crushed. In addition, due to the fact that the crushing hammers cannot be arranged on the material falling point side, the influence of the falling materials on the crushing hammers is effectively reduced, and the accidents such as jamming at the material falling point are avoided. Moreover, the feeding hole is formed in one side of the end part, so that the falling materials do not interfere with the materials hit in the crushing bin, and the feeding disorder is reduced.
Owner:宋加龙

Methods and Pharmaceutical Composition for the Treatment of a Feeding Disorder with Early-Onset in a Patient

The present invention relates to a compound which is an agonist of the oxytocin receptor o for use in the treatment of a feeding disorder with early-onset. In a particular embodiment, the agonist of the oxytocin receptor is the oxytocin or an active fragment thereof.
Owner:INST NAT DE LA SANTE & DE LA RECHERCHE MEDICALE (INSERM) +2

Method of diagnosing neurophsychiatric diseases, eating disorders or metabolic diseases

The application relates to a method of diagnosing neuropsychiatric diseases, eating disorders and / or metabolic diseases, which comprises: (i) measuring the affinity and / or the avidity of antibodies, derived from a biological sample, directed against a biological molecule involved in homeostatic regulation and / or in motivational behavior and / or in emotion; (ii) comparing the affinity value obtained with a control value.
Owner:FETISSOV SERGUEI +1
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products